The role of Toll-like receptor 3 and 4 in regulating the function of mesenchymal stem cells isolated from umbilical cord

International Journal of Molecular Medicine

Volumn 35, Issue 4, 2015, Pages 1003-1010

  Zhang, Li ^a   Liu, Dan ^a   Pu, Dan ^a   Wang, Yanwen ^a   Li, Li ^a   He, Yanqi ^a   Li, Yalun ^a   Li, Lei ^a   Qiu, Zhixin ^a   Zhao, Shuang ^a   Li, Weimin ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Biological functions; Immunogenicity; Lipopolysaccharide; Polyinosinic:polycytidylic acid; Toll like receptor 3 and 4; Umbilical cord derived mesenchymal stem cells

Indexed keywords

B7 ANTIGEN; BETA CATENIN; CCL1 CHEMOKINE; CD74 ANTIGEN; CD86 ANTIGEN; CDC2 PROTEIN; ENDOGLIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HOMEODOMAIN PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 4; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; MUSCLE SEGMENT HOMEOBOX PROTEIN; PROTEIN; STAT3 PROTEIN; SYNAPTOPHYSIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE STATUS; MESENCHYMAL STEM CELL; OSTEOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; UMBILICAL CORD; UMBILICAL CORD DERIVED MESENCHYMAL STEM CELL; UPREGULATION; AGONISTS; CELL COMMUNICATION; CELL SELF-RENEWAL; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOBLAST;

BIOMARKERS; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL SELF RENEWAL; CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; UMBILICAL CORD;

EID: 84923698816     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2106     Document Type: Article

References (26)

1. Phinney DG and Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 25: 2896-2902, 2007.
2. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW and Yarmush ML: Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47: 1634-1643, 2008.
3. Bassi EJ, Aita CA and Câmara NO: Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? World J Stem Cells 3: 1-8, 2011.
4. Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom HJ, Kim MG, Oh KH, Ahn C and Yang J: Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl Immunol 25: 7-15, 2011.
5. Le Blanc K, Frassoni F, Ball L, et al; Developmental Committee of the European Group for Blood and Marrow Transplantation: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 371: 1579-1586, 2008.
6. Vojtassák J, Danisovic L, Kubes M, Bakos D, Jarábek L, Ulicná M and Blasko M: Autologous biograft and mesenchymal stem cells in treatment of the diabetic foot. Neuro Endocrinol Lett 27 (Suppl 2): 134-137, 2006.
7. Guiducci S, Porta F, Saccardi R, et al: Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: A case report. Ann Intern Med 153: 650-654, 2010.
8. Kharaziha P, Hellström PM, Noorinayer B, et al: Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: A phase I-II clinical trial. Eur J Gastroenterol Hepatol 21: 1199-1205, 2009.
9. Sun L, Wang D, Liang J, et al: Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62: 2467-2475, 2010.
10. Allison M: Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 27: 966-967, 2009.
11. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC and Moretta L: Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107: 1484-1490, 2006.
12. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R and Fibbe WE: Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108: 2114-2120, 2006.
13. Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell 124: 783-801, 2006.
14. Blasius AL and Beutler B: Intracellular Toll-like receptors. Immunity 32: 305-315, 2010.
15. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E and Flavell RA: Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10: 1366-1373, 2004.
16. Ghosh TK, Mickelson DJ, Solberg JC, Lipson KE, Inglefield JR and Alkan SS: TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-α. Int Immunopharmacol 7: 1111-1121, 2007.
17. Lombardo E, DelaRosa O, Mancheño-Corvo P, Menta R, Ramírez C and Büscher D: Toll-like receptor-mediated signaling in human adipose-derived stem cells: Implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 15: 1579-1589, 2009.
18. Opitz CA, Litzenburger UM, Lutz C, et al: Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27: 909-919, 2009.
19. Miranda HC, Herai RH, Thomé CH, Gomes GG, Panepucci RA, Orellana MD, Covas DT, Muotri AR, Greene LJ and Faça VM: A quantitative proteomic and transcriptomic comparison of human mesenchymal stem cells from bone marrow and umbilical cord vein. Proteomics 12: 2607-2617, 2012.
20. Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS, Wu CH, Lin WY and Cheng SM: Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 8: e72604, 2013.
21. Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, Shih YH, Ko MH and Sung MS: Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: Potential therapeutic application for Parkinsonism. Stem Cells 24: 115-124, 2006.
22. Shi M, Liu ZW and Wang FS: Immunomodulatory properties and therapeutic application of mesenchymal stem cells. Clin Exp Immunol 164: 1-8, 2011.
23. Li Y and Lin F: Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120: 3436-3443, 2012.
24. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES and Scandurro AB: Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26: 99-107, 2008.
25. Huang YC, Parolini O, La Rocca G and Deng L: Umbilical cod versus bone marrow-derived mesenchymal stromal cells. Stem Cells Dev 21: 2900-2903, 2012.
26. DelaRosa O and Lombardo E: Modulation of adult mesenchymal stem cells activity by Toll-like receptors: Implications on therapeutic potential. Mediators Inflamm 2010: 865601, 2010.